Can jardiance cause weight loss
Pro Research Analysisby 
Searched over 200M research papers
Can Jardiance Cause Weight Loss?
Introduction to Jardiance and SGLT2 Inhibitors
Jardiance, known generically as empagliflozin, is a medication used primarily for the treatment of type 2 diabetes mellitus (T2DM). It belongs to a class of drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors. These inhibitors work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion through urine, a process known as glucosuria 12.
Mechanism of Action and Weight Loss
The primary mechanism by which Jardiance induces weight loss is through the promotion of glucosuria. By preventing glucose reabsorption in the renal tubules, empagliflozin causes the body to excrete excess glucose, which results in a loss of calories . This calorie loss is directly associated with a reduction in body weight. Clinical trials have demonstrated that patients taking empagliflozin experience an average weight reduction of approximately 2 kilograms .
Clinical Evidence Supporting Weight Loss
Several controlled trials have confirmed the weight loss benefits of empagliflozin. In studies ranging from 24 to 104 weeks, patients treated with empagliflozin showed significant reductions in body weight compared to those on placebo . Additionally, empagliflozin has been shown to provide similar glucose control to other diabetes medications like metformin and glimepiride, with the added advantage of promoting weight loss .
Additional Benefits and Considerations
Beyond weight loss, empagliflozin offers other health benefits, including cardiovascular protection and blood pressure reduction. The EMPA-REG OUTCOME trial highlighted its cardiovascular protective effects, making it a valuable option for patients with T2DM who are at risk of heart disease . However, it is important to note that empagliflozin can increase the risk of mycotic genital infections, particularly in women, and may cause mild urinary tract infections .
Conclusion
In summary, Jardiance (empagliflozin) is an effective SGLT2 inhibitor for managing type 2 diabetes mellitus, with the added benefit of promoting weight loss. The mechanism of action involves increased glucose excretion, leading to calorie loss and subsequent weight reduction. Clinical trials have consistently shown that empagliflozin helps patients lose weight while also providing cardiovascular and renal protective effects. However, patients should be aware of potential side effects and consult their healthcare provider to determine if Jardiance is the right choice for their treatment plan.
Sources and full results
Most relevant research papers on this topic